Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00953147 · ClinicalTrials.gov registry record · Phase 3
A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,110
- Enrollment target
NCT00953147 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 1,110 participants.
The verdict
NCT00953147, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,110 participants
- Enrollment target
Study Summary
This is a 6-month multi-center, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of ciclesonide HFA nasal aerosol administered once-daily to male and female subjects 12 years or older diagnosed with perennial allergic rhinitis (PAR).
Interventions
- DRUG Placebo
- DRUG Ciclesonide HFA 80 mcg
- DRUG Ciclesonide HFA 160 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,110 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00953147
The ClinicalTrials.gov registry entry for NCT00953147 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00953147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00953147 about?
NCT00953147 is a clinical study titled "A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older". This is a 6-month multi-center, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of ciclesonide HFA nasal aerosol administered once-daily to male and female subjects 12 years or older diagnosed with perennial allergic rhinitis (PAR).
What is the current status of trial NCT00953147?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,110 participants. The study started on 2009-08. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00953147?
The interventions under investigation include: Placebo (DRUG), Ciclesonide HFA 80 mcg (DRUG), Ciclesonide HFA 160 mcg (DRUG).
Who is sponsoring clinical trial NCT00953147?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.